加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$7.75
+US$0.02 · +0.26%
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
前收盘价
US$7.75
+US$0.02 · +0.26%
盘前
US$7.66
−US$0.09 · -1.16%
10月13日 4:49 ET
盘中时间采用ET。市场数据可能有所延迟。
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
日内区间
当前US$7.75
52周区间
当前US$7.75
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
91
深度低估
情绪
44
多空交织
风险
59
风险偏高
动量
53
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
日内区间
当前US$7.75
52周区间
当前US$7.75
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.97亿 USD | 2.66亿 USD | 2.02亿 USD | 1.49亿 USD | 9967.3万 USD |
| 销货成本 | 1.04亿 USD | 8397万 USD | 6155.9万 USD | 5884.2万 USD | 4353.4万 USD |
| 毛利 | 1.93亿 USD | 1.82亿 USD | 1.41亿 USD | 8977.4万 USD | 5613.9万 USD |
| 研究与开发 | 957.6万 USD | 917.2万 USD | 1542.5万 USD | 674.2万 USD | 206.4万 USD |
| 销售、一般及管理费用 | 2.21亿 USD | 1.98亿 USD | 1.65亿 USD | 1.42亿 USD | 1.12亿 USD |
| 营业费用 | 2.3亿 USD | 2.17亿 USD | 1.9亿 USD | 1.55亿 USD | 1.01亿 USD |
| 利息收入 | 193.1万 USD | 326.3万 USD | 86万 USD | 11.9万 USD | 1000 USD |
| 利息支出 | 1969.4万 USD | 1873.5万 USD | 1383.2万 USD | 909.7万 USD | 139.6万 USD |
| 折旧和摊销 | 874.3万 USD | 602万 USD | 586.7万 USD | 449.7万 USD | 631.4万 USD |
| 营业利润 | −3760万 USD | −3441.1万 USD | −4923.3万 USD | −6533万 USD | −4440.5万 USD |
| 净利润 | −5164.1万 USD | −5042万 USD | −6168.5万 USD | −7441.2万 USD | −4681万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$18.40
上涨空间 137.42%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1404.4万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1205.14万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF696.76万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO415.84万0.03%139.17亿 USD0.24%US$353.71-0.86%
State Street SPDR S&P Pharmaceuticals ETFXPH323.08万0.70%4.69亿 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO310.39万0.02%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA237.69万0.01%217.13亿 USD0.03%US$32.66-0.40%
iShares U.S. Pharmaceuticals ETFIHE157.89万0.10%15.52亿 USD0.37%US$100.19+0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
